Abstract
Circulating microRNAs (miRNA) are a novel class of stable, minimally invasive disease biomarkers that are valuable in diagnostics and therapeutics. miR-21 is an oncogenic miRNA that regulates the expression of multiple cancer-related target genes and it is highly expressed in the patients' serum suffering from breast cancer. The focus of the present study was on measuring the expression profile of the most significantly up-regulated miR-21 in breast cancer patients' serum to evaluate their correlation with the clinical stage of cancer by using a molecular beacon probe. miR-21 expression was also quantitatively analysed by TaqMan real-time PCR techniques. Ten serum samples from the confirmed breast cancer patients and one healthy control sample were used for the evaluation of miR-21 gene expression. The expression levels of miR-21 were significantly higher in breast cancer serum samples compared to healthy control samples with significant differences corresponding to clinical stages of II, III, and IV. The findings indicate that serum miR-21 would serve as a potential marker for therapeutic regimes as well as monitoring the patient status by a simple blood test.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Biomedical Engineering and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
